10x Genomics (NASDAQ:TXG) Releases Earnings Results, Beats Expectations By $0.12 EPS

10x Genomics (NASDAQ:TXG) posted its quarterly earnings results on Thursday. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.12, FiscalAI reports. 10x Genomics had a negative net margin of 12.18% and a negative return on equity of 9.33%. The business had revenue of $150.67 million during the quarter, compared to the consensus estimate of $147.96 million. During the same period in the previous year, the firm posted ($0.22) earnings per share. 10x Genomics’s revenue for the quarter was up 1.1% compared to the same quarter last year.

Here are the key takeaways from 10x Genomics’ conference call:

• Third-quarter revenue was $150.7 million, up 1% year over year, and 10X raised its 2026 revenue outlook to $625 million–$635 million. Excluding patent-litigation settlement revenue, the range implies 4%–6% growth over 2025.
• Atera commercial shipments began in September, and the company now expects to ship about 50 instruments by year-end, up from its prior estimate of 40. Management cited strong demand, while noting that production, installation, and customer training—not orders—are limiting the pace of rollout.
• Spatial consumables revenue grew 16%, with strong Xenium demand; management expects double-digit spatial consumables growth in Q4 as Atera consumables shipments begin. It said customer interest in Atera’s whole-transcriptome option has exceeded expectations.
• Instrument revenue fell 43% as sales of Chromium, Visium, and Xenium instruments declined, partly reflecting customers waiting for Atera. Gross margin was 75% in Q3, but management expects it to fall to the low-to-mid 60% range in Q4 and to be lower in 2027 as Atera placements make the mix more instrument-heavy.
• Single-cell reaction volumes grew at a double-digit rate, supported by Flex Apex adoption, but single-cell consumables revenue rose only 1%. Management said the lower price per reaction for Apex is weighing on revenue as customers shift toward the platform.

10x Genomics Stock Performance

NASDAQ:TXG traded down $9.46 during trading hours on Thursday, hitting $58.06. The stock had a trading volume of 5,954,404 shares, compared to its average volume of 3,534,370. 10x Genomics has a one year low of $12.80 and a one year high of $102.81. The company has a market cap of $7.56 billion, a price-to-earnings ratio of -98.41 and a beta of 2.03. The business’s 50 day moving average is $74.06 and its 200-day moving average is $41.41.

Key Stories Impacting 10x Genomics

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Q3 revenue was $150.7 million, above the roughly $148 million consensus, while the loss of $0.15 per share was narrower than analysts’ expected loss of $0.27. Revenue increased 1.1% year over year. Article: 10x Genomics Reports Q3 Loss, Beats Revenue Estimates
• Positive Sentiment: The company forecast 2026 revenue of $625 million to $635 million and said it is targeting about 50 Atera shipments by year-end, providing a revenue outlook and a near-term product milestone. Article: 10x Genomics Forecasts 2026 Revenue and Atera Shipments
• Neutral Sentiment: Broader technology stocks were volatile, with a report noting a sharp Nasdaq decline followed by a bounce. That market backdrop may have added uncertainty, but the article does not identify a TXG-specific effect. Article: Dow Jones Futures Fall, Techs Bounce
• Negative Sentiment: Despite the earnings beats, TXG declined after the results. The quarter still showed only 1.1% year-over-year revenue growth and a net loss, which may have tempered investor enthusiasm. Article: Q3 Sales Top Estimates but Stock Drops

Analyst Ratings Changes

TXG has been the subject of several recent research reports. Leerink Partners upped their target price on shares of 10x Genomics from $40.00 to $90.00 and gave the company a “market perform” rating in a research report on Tuesday, September 29th. Royal Bank Of Canada started coverage on 10x Genomics in a research report on Tuesday, September 1st. They issued a “sector perform” rating and a $70.00 price target on the stock. Stifel Nicolaus set a $70.00 price objective on 10x Genomics in a research note on Tuesday, October 13th. Barclays upped their price objective on 10x Genomics from $52.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Finally, Citigroup increased their target price on 10x Genomics from $45.00 to $50.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Five research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $68.00.

Insider Buying and Selling

In other news, CFO Adam Taich sold 46,388 shares of 10x Genomics stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $64.57, for a total transaction of $2,995,273.16. Following the transaction, the chief financial officer directly owned 316,344 shares of the company’s stock, valued at $20,426,332.08. This trade represents a 12.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Shehnaaz Suliman sold 5,723 shares of the business’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $81.19, for a total transaction of $464,650.37. Following the completion of the transaction, the director directly owned 23,792 shares of the company’s stock, valued at $1,931,672.48. This trade represents a 19.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 179,333 shares of company stock valued at $11,810,070. 8.84% of the stock is owned by company insiders.

About 10x Genomics

10x Genomics, Inc is a life sciences technology company that develops tools for analyzing biological systems at the single-cell and spatial levels. Its technologies are designed to help researchers study gene expression, cellular interactions, tissue organization and other biological processes in greater detail than conventional laboratory methods.

The company’s product portfolio includes the Chromium platform for single-cell analysis, the Visium platform for spatial transcriptomics, and the Xenium platform for high-resolution in situ analysis of tissue samples.